From Benzinga Global Small Cap Conference: Annovis Bio CEO Now Presenting
https://www.youtube.com/watch?v=B-z-9eznBMU
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
The Past Week’s Notable Insider Buys Included Digitalbridge, Life Time, A SPAC And More
Insider buying can be an encouraging signal for potential investors, especially when markets are uncertain.
With the new earnings season underway, this week's most notable insider purchases were made by 10% owners.
44 Biggest Movers From Yesterday
Gainers
Benessere Capital Acquisition Corp. (NASDAQ: BENER) shares jumped 66.5% to close at $0.4530 on Thursday.
3 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
EXCLUSIVE: Annovis Bio CEO Says Co. Planning To Continue Trials For ANVS401 Into Phase 3 For Both Parkinson’s And Alzheimer’s
https://www.youtube.com/watch?v=5KqPqg3Ae8Yhttps://www.youtube.com/watch?v=5KqPqg3Ae8Y
EXCLUSIVE: Annovis Bio President & CEO, Maria L. Maccecchini, Ph.D. Now Interviewing On Benzinga’s Power Hour Show
Click To Tune In Here... https://www.youtube.com/watch?v=5KqPqg3Ae8Y
Benzinga Pro’s Top 5 Stocks To Watch For Tuesday, Oct. 5, 2021: RIDE, RL, CCXI, ANVS, PROG
Today's 5 Stock Ideas:
Lordstown Motors (RIDE) - The stock was downgraded to Underweight (the equivalent of a sell ratings) by an analyst at Morgan Stanley. The analyst set a $2 price target on
EXCLUSIVE: Annovis Bio’s Parkinson’s Candidate Improves Speed, Motor Function Vs Placebo
Annovis Bio Inc (NYSE: ANVS) has announced efficacy data from the Phase 2 trial evaluating ANVS401 in Parkinson's disease (PD).
Data from 54 patients found that once-daily ANVS401 was superior to placebo in improving motor function.